A machine learning model can use patient-reported data and remote therapeutic monitoring to accurately assess low disease ...
Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced interim safety ...
Patients with rheumatoid arthritis-associated lung disease demonstrate a significant increased risk for serious infection vs.
New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, ...
Sonoma Biotherapeutics has announced positive interim results from its ongoing phase 1 Regulate-RA trial evaluating ...
With $70 million and a phase 2 ready asset in hand, British biotech Elevara Medicines has emerged to try to revolutionize the ...
Co-led b y Forbion and Sofinnova Partners, along with founding investor Monograph Capital, and WeatherdenInnovative lead program, ELV001, ...
Kymera Therapeutics recently presented new preclinical data for its oral IRF5 degrader KT-579 at the American College of Rheumatology 2025 meeting, showing disease-modifying activity in lupus and ...
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to appro ...
The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...
Your mouth's health significantly impacts your entire body, new research reveals. Poor oral hygiene is linked to serious ...
Armstrong highlights Artax’s focus on moving into other autoimmune diseases like rheumatoid arthritis and atopic dermatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback